Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

por Ozbay Kurt, Feyza Gul, Lasser, Samantha, Arkhypov, Ihor, Utikal, Jochen, Umansky, Viktor
Publicado 2023

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

por Lepper, Alisa, Bitsch, Rebekka, Özbay Kurt, Feyza Gül, Arkhypov, Ihor, Lasser, Samantha, Utikal, Jochen, Umansky, Viktor
Publicado 2023

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2

por Özbay Kurt, Feyza Gül, Lepper, Alisa, Gerhards, Catharina, Roemer, Mathis, Lasser, Samantha, Arkhypov, Ihor, Bitsch, Rebekka, Bugert, Peter, Altevogt, Peter, Gouttefangeas, Cécile, Neumaier, Michael, Utikal, Jochen, Umansky, Viktor
Publicado 2022

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling

por Arkhypov, Ihor, Özbay Kurt, Feyza Gül, Bitsch, Rebekka, Novak, Daniel, Petrova, Vera, Lasser, Samantha, Hielscher, Thomas, Groth, Christopher, Lepper, Alisa, Hu, Xiaoying, Li, Wei, Utikal, Jochen, Altevogt, Peter, Umansky, Viktor
Publicado 2022